Peptide record

TPDB64857

ASA-ApoEI Blood-Brain Barrier modified_plain modified
23 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

Standard-residue backbone model; source-recorded chemical modifications are not verified in these coordinates.

TPDB64857
ASA-ApoEI
Blood-Brain Barrier
Delivery and barrier-penetrating peptides
B3Pred BBPpredict Peptipedia
modified_plain
Yes
A 23-aa modified blood-brain barrier peptide sequence curated from B3Pred, BBPpredict, and Peptipedia, with an available 3D structural model.
N-terminal: Conjugated with ASA drug
Sequence
TEELRVRLASHLRKLRKRLLRDA
Physicochemical Analysis

Sequence-only estimates are not provided for modified or non-standard source notation. Reported molecular properties, when available, are retained below with their source records.

Chemical Descriptors
23 reviewed residue count
Linear Activity
Conjugated with ASA drug Activity
ThrGluGluLeuArgValArgLeuAlaSerHisLeuArgLysLeuArgLysArgLeuLeuArgAspAla Activity
Evidence Records 3 records
Evidence 1 Activity

Activity

Blood-Brain Barrier

Target

CHO cell line

Assay & Model

2.5 microgram/ ml
cellular uptake assay
93 % cellular uptake
Lysosomal disorder

Source & Reference

NA
B3Pdb

Other

Transendocytosis
Evidence 2 Activity

Activity

Blood-Brain Barrier

Target

bEND cell line

Assay & Model

2.5 microgram/ ml
cellular uptake assay
21.2 % cellular uptake
Lysosomal disorder

Source & Reference

NA
B3Pdb

Other

Transendocytosis
Evidence 3 Activity

Activity

Blood-Brain Barrier

Target

PBCECs cell line

Assay & Model

0.02% cells were added
Basolateral screening assay
200% transfer
Lysosomal disorder

Source & Reference

NA
B3Pdb

Other

Basolateral